SCHEMBL1901499

SCHEMBL1901499

CCCCCCCCCCCCCCC(O)C(N)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 1.00
SPHK1 Q9NYA1 4/20 1.00
LMNA P02545 4/20 1.00
MAPT P10636 4/20 1.00
GMNN O75496 3/20 1.00
POLB P06746 3/20 1.00
BLM P54132 3/20 1.00
CETP P11597 3/20 1.00
UBE2N P61088 3/20 1.00
THPO P40225 2/20 1.00
TP53 P04637 2/20 1.00
CYP1A2 P05177 2/20 1.00
MTOR P42345 1/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP3A4 P08684 1/20 1.00
HTT P42858 1/20 1.00
CSNK1E P49674 1/20 0.54
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
GLA P06280 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1907293 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL18127645 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
Dihydrospingosine SCHEMBL7106054 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL8746720 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
Dihydrospingosine SCHEMBL3509781 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
Dihydrospingosine SCHEMBL13285654 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
Dihydrospingosine SCHEMBL1905632 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL21660227 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL21431064 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL12330726 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024219793-A1 MARKER FOR PREDICTING GROWTH RATE OF UTERINE FIBROIDS, AND USE THEREOF 한국 한의학 연구원 2024-10-24 WO claimed
EP-3773919-A1 METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS Pepsis Limited (GB) 2021-02-17 EP claimed
WO-2019186141-A1 METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS Pepsis Limited (GB) 2019-10-03 WO claimed
EP-2424554-B1 NOVEL SPHINGOSINE KINASE TYPE 1 INHIBITORS, COMPOSITIONS AND PROCESSES FOR USING SAME ENZO THERAPEUTICS INC (US) 2025-01-15 EP disclosed
WO-2024219793-A1 MARKER FOR PREDICTING GROWTH RATE OF UTERINE FIBROIDS, AND USE THEREOF 한국 한의학 연구원 2024-10-24 WO disclosed
WO-2024219793-A1 MARKER FOR PREDICTING GROWTH RATE OF UTERINE FIBROIDS, AND USE THEREOF 한국 한의학 연구원 2024-10-24 WO disclosed
US-20240210421-A1 Methods of Predicting Atopic Dermatitis NATIONAL JEWISH HEALTH 2024-06-27 US disclosed
US-11529370-B2 Use of composition comprising stem cell-derived exosome as effective ingredient in strengthening skin barrier and improving skin barrier function EXOCOBIO INC. (KR) 2022-12-20 US disclosed
EP-3773919-A1 METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS Pepsis Limited (GB) 2021-02-17 EP disclosed
WO-2019186141-A1 METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS Pepsis Limited (GB) 2019-10-03 WO disclosed
US-20190117590-A1 Compositions and Methods for Treating Hyperproliferative Disorders TEXAS TECH UNIVERSITY SYSTEM 2019-04-25 US disclosed
EP-2669267-A1 Compositions and methods for treating hyperproliferative disorders TEXAS TECH UNIVERSITY (US) 2013-12-04 EP disclosed
EP-2501672-A2 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS TEXAS TECH UNIVERSITY (US) 2012-09-26 EP disclosed
US-20110152267-A1 Compositions and Methods for Treating Hyperproliferative Disorders TEXAS TECH UNIVERSITY SYSTEM 2011-06-23 US disclosed
WO-2011060332-A2 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS TEXAS TECH UNIVERSITY (US) 2011-05-19 WO disclosed
US-7811602-B2 Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2010-10-12 US disclosed
EP-1750673-B1 LIPOSOMAL FORMULATIONS COMPRISING DIHYDROSPHINGOMYELIN AND METHODS OF USE THEREOF TEKMIRA PHARMACEUTICALS CORP (CA) 2009-12-02 EP disclosed
EP-1750673-A2 LIPOSOMAL FORMULATIONS COMPRISING DIHYDROSPHINGOMYELIN AND METHODS OF USE THEREOF Inex Pharmaceuticals Corporation (CA) 2007-02-14 EP disclosed
US-20060008909-A1 Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof INEX PHARMACEUTICALS CORPORATION (CA) 2006-01-12 US disclosed
WO-2005120461-A2 LIPOSOMAL FORMULATIONS COMPRISING DIHYDROSPHINGOMYELIN AND METHODS OF USE THEREOF INEX PHARMACEUTICALS CORPORATION (CA) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117590-A1 Compositions and Methods for Treating Hyperproliferative Disorders SGMS1, S1PR1, SPHK1 CYP2D6 4551/4885SPHK1 3/4885LMNA 1618/4885
US-20110152267-A1 Compositions and Methods for Treating Hyperproliferative Disorders SGMS1, S1PR1, SPHK1 CYP2D6 4551/4885SPHK1 3/4885LMNA 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.